Transcription factor E2-alpha (TCF3) (TCF3)

Transcription factor E2-alpha (TCF3) is a critical member of the basic helix-loop-helix (bHLH) family of transcription factors, primarily known for its two splice variants, E12 and E47 (UniProt P15923). These proteins, collectively referred to as E2A, are indispensable for the development of B and T lymphocytes, where they regulate the expression of genes involved in lineage commitment and antigen receptor rearrangement (NCBI Gene ID: 6929). The target DNA via E12 heterodimerization refers to the functional mechanism by which E12 forms heterodimers with other bHLH proteins to bind specific DNA sequences known as E-boxes (CANNTG) (PMID: 10648606). In clinical oncology, TCF3 is frequently implicated in acute lymphoblastic leukemia (ALL) through chromosomal translocations, most notably the t(1;19) translocation which generates the oncogenic E2A-PBX1 fusion protein (PMID: 21844325). Therapeutic strategies targeting this pathway aim to disrupt the dimerization or DNA-binding capacity of E12/E47 or their fusion counterparts to arrest leukemic cell growth. While small molecule inhibitors and peptide mimetics are being explored in preclinical research, targeting these transcription factors remains a significant challenge due to the absence of traditional small-molecule binding pockets. Additionally, endogenous inhibitors such as Id proteins naturally regulate E12 activity by sequestering it away from DNA binding sites.

Other names

E2AE12E47Transcription factor 3bHLHb21Kappa-E2-binding factorDNA via E12 heterodimerization

Inhibition of DNA binding through disruption of bHLH protein-protein heterodimerization or competitive binding to E-box sequences.